New treatment shown to reduce recurrence of debilitating diarrhoea
Thursday, January 21, 2010 - 12:35
in Health & Medicine
A combination of two fully human monoclonal antibodies developed by MassBiologics (MBL) of the University of Massachusetts Medical School (UMMS) and Medarex, a wholly owned subsidiary of Bristol-Myers Squibb Co. (NYSE:BMY), when given with standard antibiotics, was shown to reduce recurrence of a debilitating form of diarrhoea by 72 percent in patients enrolled in a Phase 2 clinical trial. The results of the trial are reported in the article 'Treatment with Monoclonal Antibodies against Clostridium difficile Toxins' to be published 21 January in the New England Journal of Medicine (NEJM)...